A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 11525-11525
Author(s):  
Lina Tang ◽  
Xiaohui Niu ◽  
Zhen Wang ◽  
Qiqing Cai ◽  
Chongqi Tu ◽  
...  
Keyword(s):  
Phase Ii ◽  
Malignant Fibrous Histiocytoma ◽  
Bone Tumor ◽  
Ewing Sarcoma ◽  
Phase Ii Study ◽  
Fibrous Histiocytoma ◽  
Malignant Bone Tumor ◽  
Eligibility Criteria ◽  
Primary Malignant Bone Tumor ◽  
Study Results

11525 Background: Primary malignant bone tumors are rare forms of cancer and include mainly bone sarcomas, which are categorized into 3 common types based on tissue origin: osteosarcoma, chondrosarcoma and Ewing sarcoma. A phase II trial was designed to explore the anlotinib activity in patients with relapsed or metastatic primary malignant bone tumor. Methods: Eligible pts were received 12mg of anlotinib once daily, 2 weeks on and 1 week off until progression or unacceptable toxicity. Key-eligibility criteria were aged 14-70 years, histologically confirmed diagnosis of osteosarcoma, chondrosarcoma, bone derived malignant fibrous histiocytoma, giant cell tumor, Ewing sarcoma and PNET, confirmed previous chemotherapy failure, ECOG 0-1(0-2 for amputation pts), required at least one measurable lesion. We observed PFS, OS, ORR, DCR and AE in this study. Results: From August 2018 to April 2019, 42 pts were included. Of 42 efficacy-evaluable pts, 25 were man, median age was 28 (14-68) years. There were 29 pts of osteosarcoma, 9 pts of chondrosarcoma, 3pts of Ewing sarcoma and 1 pt of bone derived malignant fibrous histiocytoma. The progression-free rate at 12 weeks (PFR12weeks), ORR and DCR were 71.3%, 9.52% and 78.57%. Median PFS was 5.26 months (95%CI = 3.48-8.44). Median OS was 11.40 months (95%CI = 10.09, [ ). Median PFS of osteosarcoma and chondrosarcoma was 4.83 months (95%CI = 3.48, 7.13 ) and 2.76 months (95%CI = 1.31, [ ) respectively. The most common Gr 3-5 anlotinib-related AEs were hypertension (19.05%), hypertriglyceridemia (9.52%), hand-foot syndrome (7.14%), and proteinuria (4.76%). Conclusions: The phase II study shows a promising activity of anlotinib in patients with relapsed or metastatic primary malignant bone tumor and an acceptable toxicity. Clinical trial information: NCT03527888 .

Sensitive Osteosarcoma Diagnosis Through Five-Base Telomerase Product-Triggered CRISPR-Cas12a Enhanced Rolling Circle Amplification

2021 ◽  
Author(s):  
Xing Zhou ◽  
Jun-Liang Zhang ◽  
Meng-Han Chang ◽  
Gentao Fan ◽  
Xiao-Zhou Liu ◽  
...  
Keyword(s):  
Early Diagnosis ◽  
Bone Tumor ◽  
Rolling Circle Amplification ◽  
Mesenchymal Cells ◽  
Pivotal Role ◽  
Sensitive Detection ◽  
Malignant Bone Tumor ◽  
Rolling Circle ◽  
Primary Malignant Bone Tumor

Osteosarcoma is the most frequent primary malignant bone tumor composed of mesenchymal cells producing osteoid and immature bone. Sensitive detection of telomerase plays a pivotal role for the early diagnosis...

Low-heat Treated Intercalary Autograft Reconstruction in Limb Salvage of Primary Malignant Bone Tumor

2007 ◽  
Vol 42 (3) ◽  
pp. 291
Author(s):  
Han-Soo Kim ◽  
Hyun Guy Kang ◽  
Jai Ho Cho ◽  
Kap Jung Kim ◽  
Joo Han Oh ◽  
...  
Keyword(s):  
Limb Salvage ◽  
Bone Tumor ◽  
Malignant Bone Tumor ◽  
Primary Malignant Bone Tumor ◽  
Heat Treated

scholarly journals P14.120 Phase II study of weekly carboplatin in pretreated adult malignant gliomas

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii97-iii97
Author(s):  
V Villani ◽  
A Pace ◽  
A Vidiri ◽  
A Tanzilli ◽  
F Sperati ◽  
...  
Keyword(s):  
Malignant Glioma ◽  
Phase Ii ◽  
Clinical Benefit ◽  
Phase Ii Study ◽  
Karnofsky Performance Status ◽  
Performance Status ◽  
Single Agent ◽  
Malignant Gliomas ◽  
Recurrent Malignant Glioma ◽  
Eligibility Criteria

Abstract BACKGROUND Patients with relapse of recurrent glioma have a poor outcome and limited treatment options. The aim of this study is to investigate the clinical benefit and tolerability of weekly intravenous administration of carboplatin-based monotherapy in adult glioma patients who had progressed from previous chemotherapy lines based on temozolomide and nitrosoureas MATERIAL AND METHODS This was a single arm, Phase II study. Eligibility criteria included progressive or recurrent malignant glioma after radiotherapy and chemotherapy-based treatments and Karnofsky Performance Status (KPS) > 60. RESULTS Thirty-two patients (median age: 43.5 y) were enrolled to receive weekly carboplatin monotherapy in intravenous mode of administration. The median duration of response was 7.3 months with an overall disease control rate of 31.3%. Median progression-free survival (PFS) was 2.3 months while overall survival (OS) was 5.5 months. Patients achieving clinical benefit exhibited a longer PFS (4.6 vs 1.5 months; p>0.001) and OS (7.9 vs 3.2 months; p=0.041) compared to those not achieving clinical benefit. CONCLUSION Our findings show that single agent, weekly, intravenous carboplatin may have a role in the treatment patients with recurrent malignant glioma

scholarly journals Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma – Phase II study results

Neoplasma ◽  
2012 ◽  
Vol 59 (04) ◽  
pp. 440-449 ◽  
Author(s):  
L. ZAHRADOVA ◽  
K. MOLLOVA ◽  
D. OCADLIKOVA ◽  
L. KOVAROVA ◽  
Z. ADAM ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Dendritic Cell ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Dendritic Cell Vaccine ◽  
Cell Vaccine ◽  
Efficacy And Safety ◽  
Study Results ◽  
Id Protein

scholarly journals Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Edwin Choy ◽  
James E Butrynski ◽  
David C Harmon ◽  
Jeffrey A Morgan ◽  
Suzanne George ◽  
...  
Keyword(s):  
Phase Ii ◽  
Ewing Sarcoma ◽  
Phase Ii Study ◽  
Standard Chemotherapy

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study.

1998 ◽  
Vol 16 (10) ◽  
pp. 3392-3397 ◽  
Author(s):  
L Sengeløv ◽  
C Kamby ◽  
B Lund ◽  
S A Engelholm
Keyword(s):  
Peripheral Neuropathy ◽  
Phase Ii ◽  
Urothelial Cancer ◽  
Phase Ii Study ◽  
Performance Status ◽  
Single Agent ◽  
Complete Response ◽  
World Health ◽  
Eligibility Criteria ◽  
Metastatic Urothelial Cancer

PURPOSE Docetaxel and cisplatin has documented single-agent activity and different toxicity profiles in patients with metastatic urothelial cancer. We performed a phase II study in which docetaxel was combined with cisplatin to evaluate response rate, toxicity, and survival. PATIENTS AND METHODS Eligibility criteria included performance status (World Health Organization [WHO]) less than 3; normal bone marrow, liver, and renal function; and no concurrent malignancy or symptomatic peripheral neuropathy. Docetaxel (Taxotere; Rhône-Poulenc Rorer, Paris, France) 75 mg/m2 was combined with cisplatin 75 mg/m2 every third week. Patients received premedication with prednisolone and clemastine. RESULTS A total of 25 patients were assessable for response and toxicity. Median age was 64 years; five patients had locoregional disease only and 20 had metastatic disease. Response was achieved in 15 patients (60%; 95% confidence interval [CI], 39% to 79%), including seven patients (26%) who achieved a complete response. Overall median survival time was 13.6 months (range, 1.5 to 26.4+). The most frequent toxicity was nausea and vomiting (80% of patients). Neutropenia grade 3 or 4 was observed in 56% of patients, but only one had febrile neutropenia. Mucositis and diarrhea were encountered in 13% of cycles, mostly grade 1 or 2. Peripheral neuropathy and skin changes grade 1 and 2 were observed in 76% and 36%, respectively. Fluid retention and hypersensitivity reactions were infrequent and mild. CONCLUSION The combination of docetaxel and cisplatin is effective and feasible in patients with metastatic urothelial cancer with a manageable safety profile.

Sign in / Sign up

Export Citation Format

Share Document